Pulmonary tuberculosis with fixed drug eruption to all first-line anti-tuberculosis drugs

Abstract

Tuberculosis (TB) is still one of the leading causes of mortality worldwide. Treatment with anti-TB drugs sometimes results in side effects for patients, including drug reactions, both allergic and non-allergic. Cutaneous adverse drug reaction is the most common side effect of anti-TB drugs, but severe reaction is rare. Here, we report rare case of a 34-year-old male who presented with pulmonary TB and fixed drug eruption to all first-line anti-TB therapies. After ingesting anti-TB regimen, multiple skin erosions and blisters occurred. Skin biopsy was performed and result was epidermis with subepidermal bullous. The patient's condition deteriorated, he developed severe hypoxemia, and unfortunately, he died during fixed drug eruption treatment.

"A Rare Case of Stevens-Johnson Syndrome Associated with Anti-Tuberculosis Drugs"

“…The global TB death rate is decreasing at a pace of roughly 3% a year [3]. Patients may experience side effects from anti-TB medication use, including as allergic and non-allergic drug reactions [6]. Skin rash is the second most common adverse event, and drug eruptions brought on by these drugs continue to be a significant treatment barrier [7,8].…”

Steven-Johnson Syndrome associated with anti-tuberculosis drugs: a case reports

“…3 Treatment with anti-TB drugs sometimes results in side effects for patients, including drug reactions, both allergic and non-allergic. 4 The adverse reactions mainly include drug-induced liver injury, gastrointestinal reactions, and skin rash. 5 The most common adverse reaction caused by the first-line anti-tuberculosis drugs is mild liver dysfunction, while severe liver toxic effects including liver failure or even death are very rare.…”